Anti-PD-1 monoclonal antibody

Phase 2Small molecule

Anti-PD-1 monoclonal antibody is one of 337 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

336

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

RecurrentRecruiting

Melanoma Stage IVRecruiting

ImmunotherapyActive, not recruiting

Renal Cell CarcinomaRecruiting

Central Nervous System LymphomaRecruiting

Pancreatic CancerRecruiting

Soft Tissue SarcomaRecruiting

Advanced Solid TumorsRecruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

RecurrentPhase 1

Recruiting

Melanoma Stage IVPreclinical

Recruiting

ImmunotherapyPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Recruiting

Central Nervous System LymphomaPhase 2

Recruiting

Pancreatic CancerPhase 2

Recruiting

Soft Tissue SarcomaPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

6 2

SSGJ-707

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

1 3

Consolidative Therapy

SSun Yat-sen University

Phase 3

2 4

Anti-PD-1 monoclonal antibody

IiTeos Therapeutics

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Advanced Solid Tumor

NCT06603844

Phase 2Active, not recruiting

Immunotherapy

NCT05522582

Phase 1/2Recruiting

Locally Advanced/metastatic Solid Tumors

NCT05699811

Q2 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT05941507

Q4 2027

PreclinicalRecruiting

Melanoma Stage IV

NCT06425926

Phase 2Recruiting

Immunotherapy

NCT06170710

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Completed·CChen Xiaoping··NCT06298123·304 enrolled

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting·ZZe-yang Ding, MD··NCT05713994·300 enrolled

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting·TTongji Hospital··NCT05717738·300 enrolled

Advanced Solid Tumors3 trials

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Unknown status·TTaizhou Hanzhong biomedical co. LTD·Phase 2·NCT03704246·123 enrolled

A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Active, not recruiting·IiTeos Therapeutics·Phase 1·NCT06547957·55 enrolled

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting·LLigaChem Biosciences, Inc.·Phase 1/2·NCT05941507·300 enrolled

Immunotherapy3 trials

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Recruiting·—·Phase 2·NCT06170710·173 enrolled

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Active, not recruiting·—·Phase 2·NCT05522582·50 enrolled

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Recruiting·FFudan University·Phase 2·NCT06121700·55 enrolled

Lymphoma3 trials

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT04096690·22 enrolled

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05182957·40 enrolled

Tislelizumab Plus Dose-Dense P-GemOx and Radiation Therapy for Early-Stage Intermediate/High-Risk Extranodal NK/T-Cell Lymphoma: A Multicenter Phase II Trial

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT05254899·54 enrolled

Pancreatic Cancer2 trials

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Completed·ZZhejiang University·Phase 2·NCT03983057·392 enrolled

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Recruiting·—·Phase 1/2·NCT04146298·30 enrolled

18 more indications

Central Nervous System Lymphoma1 trial

A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT06556199·38 enrolled

Colorectal Cancer1 trial

A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Unknown status·SShanghai Celfuture Biotech Co., Ltd.·Phase 2·NCT05684211·84 enrolled

Non-Small Cell Lung Cancer1 trial

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

Recruiting·EEnergenx Medical LTD.·N/A·NCT05987345·10 enrolled

Recurrent1 trial

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT07090148·14 enrolled

Soft Tissue Sarcoma1 trial

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting·FFudan University·Phase 1/2·NCT05774275·52 enrolled

Renal Cell Carcinoma1 trial

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Recruiting·JJinling Hospital, China·Phase 2·NCT06255223·35 enrolled

Breast Cancer1 trial

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled

Chemotherapy1 trial

Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05307198·38 enrolled

Stereotactic Body Radiotherapy1 trial

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Recruiting·ZZhejiang Cancer Hospital·N/A·NCT06349044·120 enrolled

Radiotherapy1 trial

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05149170·30 enrolled

Advanced Solid Tumor1 trial

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Recruiting·CCorbus Pharmaceuticals Inc.·Phase 1/2·NCT06603844·156 enrolled

Gastric Adenocarcinoma1 trial

Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma

Suspended·FFudan University·Phase 2·NCT06728657·68 enrolled

Melanoma1 trial

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Unknown status·—·Phase 2·NCT04928365·50 enrolled

Anti-PD-1 Antibody1 trial

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Unknown status·SSun Yat-sen University·Phase 2·NCT04676789·30 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT07365592·138 enrolled

Locally Advanced/Metastatic Solid Tumors1 trial

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Recruiting·—·Phase 1/2·NCT05699811·40 enrolled

Neoadjuvant Treatment1 trial

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05556200·58 enrolled

Melanoma Stage IV1 trial

A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors

Recruiting·GGeorgiamune Inc·Preclinical·NCT06425926·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Anti-PD-1 monoclonal antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-PD-1 monoclonal antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-PD-1 monoclonal antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iTeos Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IiTeos Therapeutics

Anti-PD-1 monoclonal antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Advanced Solid Tumors3 trials

Immunotherapy3 trials

Lymphoma3 trials

Pancreatic Cancer2 trials

Central Nervous System Lymphoma1 trial

Colorectal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Recurrent1 trial

Soft Tissue Sarcoma1 trial

Renal Cell Carcinoma1 trial

Breast Cancer1 trial

Chemotherapy1 trial

Stereotactic Body Radiotherapy1 trial

Radiotherapy1 trial

Advanced Solid Tumor1 trial

Gastric Adenocarcinoma1 trial

Melanoma1 trial

Anti-PD-1 Antibody1 trial

Neoadjuvant Chemotherapy1 trial

Locally Advanced/Metastatic Solid Tumors1 trial

Neoadjuvant Treatment1 trial

Melanoma Stage IV1 trial

References

Drug Info

Quick Facts

Related News